drugset / Trial / NCT02346487
Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally (LIVING Study)
Phase 3
Completed
1003 enrolled
Drugs for Neglected Diseases
French Development Agency · collabUNITAID · collab
NaSingle-groupOpen-labelTreatment
Summary
The study will be carried out to provide supportive clinical data on the feasibility, efficacy, safety, and PK of LPV based therapies in routine treatment setting and will be based on the existing LPV/r pellets which already represent a clear advantage in comparison with the liquid formulation.
Timeline
- Start
- 2015-09
- Primary completion
- 2019-05-14
- Completion
- 2019-05-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABC | Unknown | 60 mg | — |
| Subject | AZT | Unknown | 60 mg | — |
| Subject | Lamivudine | Other / unclassified | 30 mg | — |
| Subject | Lopinavir | Other / unclassified | 40 mg | Oral |
| Subject | Ritonavir | Other / unclassified | 10 mg | Oral |